Theranostics 2021, Vol. 11, Issue 11 5430 Ivyspring International Publisher Theranostics 2021; 11(11): 5430-5446. doi: 10.7150/thno.53961 Review Sialylated immunoglobulin G: a promising diagnostic and therapeutic strategy for autoimmune diseases Danqi Li1,2*, Yuchen Lou1,2*, Yamin Zhang1,2, Si Liu3, Jun Li4 and Juan Tao1,2 1. Department of Dermatology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. 2. Hubei Engineering Research Center for Skin Repair and Theranostics, Wuhan, China. 3. Britton Chance Center for Biomedical Photonics at Wuhan National Laboratory for Optoelectronics-Hubei Bioinformatics & Molecular Imaging Key Laboratory, Systems Biology Theme, Department of Biomedical Engineering, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, China. 4. Department of Dermatology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology (HUST), Wuhan, China. *These authors contributed equally to this work. Corresponding authors: E-mail address:
[email protected] (J. Li),
[email protected] (J. Tao). © The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions. Received: 2020.09.30; Accepted: 2021.03.04; Published: 2021.03.13 Abstract Human immunoglobulin G (IgG), especially autoantibodies, has major implications for the diagnosis and management of a wide range of autoimmune diseases. However, some healthy individuals also have autoantibodies, while a portion of patients with autoimmune diseases test negative for serologic autoantibodies. Recent advances in glycomics have shown that IgG Fc N-glycosylations are more reliable diagnostic and monitoring biomarkers than total IgG autoantibodies in a wide variety of autoimmune diseases.